Article
The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2006
Barkan Batya, Starinsky Sigal, Friedman Eitan, Stein Reuven, Kloog Yoel
Abstract excerpt
PURPOSE: Farnesylthiosalicylic acid (FTS) is a Ras inhibitor that dislodges all active Ras isoforms from the membrane. We assessed the ability of FTS to reverse the transformed phenotype of neurofibromatosis type 1 (NF1)-associated tumor cell lines of malignant peripheral nerve sheath tumor (MPNST). EXPERIMENTAL DESIGN: nf1 mutations were genotyped, allelic losses were analyzed, and neurofibromin expression...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.